List of works - Muthiah Vaduganathan

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

scientific article published on 01 November 2019

Anticoagulation in heart failure: current status and future direction

scientific article

Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review

scientific article published on 22 December 2016

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial

article

Availability and Use of Shared Data From Cardiometabolic Clinical Trials.

scientific article published on 13 November 2017

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).

scientific article

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

scientific article published in January 2017

Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012.

scientific article published on 26 March 2016

Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial

scientific article published on May 2016

Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)

Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial

article

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial

scientific article

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVERE

article

Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations

scientific article published on July 2015

Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies

scientific article

Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012).

scientific article published on 18 April 2015

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

scientific article published on 7 October 2015

Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?

scientific article published on 19 February 2014

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

scientific article published on March 2013

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries

scientific article

Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?

scientific article published on 01 March 2019

Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis

scientific article published on August 2017

Drug therapy to reduce early readmission risk in heart failure: ready for prime time?

scientific article

Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials

scientific article published in 2023

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial

scientific article published on 30 April 2016

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

article

Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review

scientific article published on 01 October 2018

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials

scientific article

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

scientific article published in The Lancet

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

scientific article published in The Lancet

Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

article by Catherine Owens Johnson et al published March 2019 in Lancet Neurology

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Dise

scientific article published in The Lancet

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

scientific article published in The Lancet

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial

scientific article

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

scientific article published on 10 July 2019

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues

scientific article published on 16 December 2019

Hemoconcentration-guided diuresis in heart failure

scientific article

High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.

scientific article published in December 2018

History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure

scientific article published on 05 November 2018

Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.

scientific article

Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial

scientific article

Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial

scientific article published on 14 September 2019

Lipids, statins, and clinical outcomes in heart failure: rethinking the data

scientific article

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

scientific article published in The Lancet

Medicaid Expansion and Utilization of Antihyperglycemic Therapies

scientific article published on 04 September 2020

Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)

scientific article

Mode of Death in Heart Failure With Preserved Ejection Fraction

scientific article

One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry).

scientific article

Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope

scientific article published on 01 August 2018

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

scientific article published in The Lancet

Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial

scientific article published on 17 October 2017

Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

article

Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations

scientific article

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

scientific article

Progress or lack of progress in hospitalized heart failure.

scientific article published in September 2013

Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives

scientific article published on July 2013

Rehospitalization for heart failure: problems and perspectives

scientific article published on 5 December 2012

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)

scientific article published on 06 November 2018

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

scientific article

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

scientific article published on 16 September 2014

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial

scientific article published on 12 December 2012

Reply

Reply: effect of ivabradine on early readmissions after hospitalization for worsening heart failure

scientific article published in March 2015

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF

scientific article published on 09 October 2019

Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold.

scientific article

Roadmap to inpatient heart failure management

scientific article

Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.

scientific article published on 10 May 2017

Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure

scientific article published on 14 January 2016

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials

scientific article

Site selection for heart failure clinical trials in the USA.

scientific article published in July 2015

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

scientific article

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)

Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?

article

The Reply

scientific article published on 01 June 2018

The Reply

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

scientific article

The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure

scientific article published on July 2013

The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.

scientific article

The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions

scientific article

The vulnerable phase after hospitalization for heart failure

scientific article published on 10 February 2015

Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory

scientific article published on 09 December 2020

Trends in Heart Failure Clinical Trials From 2001-2012.

scientific article published on 21 June 2015

Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials

scientific article published on 19 March 2016

Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response

scientific article published on 10 September 2015

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

scientific article published on June 2016

Water and sodium in heart failure: a spotlight on congestion

scientific article published on January 2015

List of works by Muthiah Vaduganathan

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Anticoagulation in heart failure: current status and future direction

Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial

Availability and Use of Shared Data From Cardiometabolic Clinical Trials.

Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012.

Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial

Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial)

Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVERE

Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations

Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies

Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012).

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries

Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?

Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis

Drug therapy to reduce early readmission risk in heart failure: ready for prime time?

Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Dise

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues

Hemoconcentration-guided diuresis in heart failure

High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.

History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure

Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial

Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial

Lipids, statins, and clinical outcomes in heart failure: rethinking the data

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

Medicaid Expansion and Utilization of Antihyperglycemic Therapies

Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)

Mode of Death in Heart Failure With Preserved Ejection Fraction

One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry).

Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope

Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial

Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Progress or lack of progress in hospitalized heart failure.

Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives

Rehospitalization for heart failure: problems and perspectives

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial

Reply

Reply: effect of ivabradine on early readmissions after hospitalization for worsening heart failure

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF

Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold.

Roadmap to inpatient heart failure management

Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.

Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials

Site selection for heart failure clinical trials in the USA.

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial)

Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?

The Reply

The Reply

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure

The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.